围手术期化疗联合立体定向体部放疗对比单纯化疗治疗高危局限性胰腺癌(MASTERPLAN):一项开放标签、2期、多中心、随机试验
MASTERPLAN是一项在澳大利亚和新西兰14家医院开展的开放标签、随机、2期试验,评估在围手术期化疗基础上加用SBRT能否降低高危局限性胰腺导管腺癌的局部区域复发。
要点
- 在高危局限性PDAC中,化疗联合SBRT较单纯化疗显著降低12个月局部区域复发率。
- 联合SBRT未显著增加≥3级不良事件或严重不良事件的发生率。
- 该2期试验因入组缓慢提前终止,样本量小于计划,结果需更大规模研究验证。
核心结论
- 在高危局限性胰腺导管腺癌患者中,围手术期化疗联合SBRT与显著降低的局部区域复发相关,且未显著增加毒性,值得在更大规模研究中进一步探索。
研究设计与样本
- MASTERPLAN为开放标签、随机、2期试验,在澳大利亚和新西兰14家医院开展,计划入组120例但因入组缓慢于2025年1月6日提前停止招募。
- 2020年2月26日至2025年1月6日共随机分配74例患者(58%男性,42%女性),按2:1分配至化疗+SBRT组(n=49)或单纯化疗组(n=25)。
- eligible participants为年龄≥18岁、ECOG体能状态0-1、既往未治疗的局限性PDAC且至少具有一项高危特征(肿瘤>4 cm、胰外侵犯、淋巴结阳性、交界可切除或局部晚期)。
- 化疗方案为研究者选择的mFOLFIRINOX或吉西他滨联合白蛋白紫杉醇;SBRT为40 Gy分5次,每周2-4次,并实施实时放疗质量保证。
- 主要终点为意向治疗人群的12个月局部区域复发,安全性终点按实际接受治疗分析。
主要发现
- 最常见的3-4级不良事件为腹泻(SBRT组7例[15%] vs 单纯化疗组5例[20%])和血栓栓塞事件(3例[6%] vs 1例[4%])。
- 归因于SBRT的严重不良事件共2例:2级小肠梗阻和3级胰腺炎。
关键数值与推荐
- 高危局限性PDAC定义包括:肿瘤大小>4 cm、胰外侵犯、淋巴结阳性、交界可切除疾病或局部晚期疾病。
- SBRT剂量为40 Gy分5次,每周2-4次。
- mFOLFIRINOX方案:第1天奥沙利铂85 mg/m2、伊立替康150 mg/m2、亚叶酸钙50 mg、氟尿嘧啶2400 mg/m2持续46小时,每14天一次,共6周期。
- 吉西他滨联合白蛋白紫杉醇方案:第1、8、15天吉西他滨1000 mg/m2和白蛋白紫杉醇125 mg/m2,每28天一次,共3周期。
- 术后辅助化疗计划12周,可选mFOLFIRINOX或吉西他滨联合卡培他滨(吉西他滨1000 mg/m2静脉第1、8、15天,卡培他滨830 mg/m2口服每日两次第1-21天,28天周期);不适合手术者继续同方案化疗额外12周,总计划化疗时长24周。
临床怎么用
- 对于具有高危特征的局限性PDAC,可考虑在围手术期化疗基础上加用SBRT以降低局部区域复发风险。
- SBRT的毒性总体可管理,但需注意小肠梗阻和胰腺炎等放疗相关不良事件。
- 该结果为2期试验,样本量有限,尚不能改变常规实践,需在更大规模3期试验中验证。
局限性
- 试验因入组缓慢提前终止,实际样本量74例低于计划120例,统计效能受限。
- 开放标签设计可能引入偏倚。
- 化疗方案由研究者选择,存在异质性。
- 部分安全性分析基于实际治疗人群,样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has poor outcomes and high rates of locoregional recurrence. MASTERPLAN evaluated whether stereotactic body radiotherapy (SBRT) reduced locoregional recurrence in patients with high-risk, localised PDAC. METHODS: MASTERPLAN was an open-label, randomised, phase 2 trial conducted across 14 hospitals in Australia and New Zealand. Eligible participants were aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1, and had previously untreated localised PDAC with at least one high-risk feature, including tumour size more than 4 cm, extrapancreatic extension, node-positive disease, borderline resectable disease, or locally advanced disease. Participants were randomly assigned (2:1) using the method of minimisation to investigator-choice chemotherapy, with or without SBRT, stratified by participant cohort (potentially operable vs inoperable), planned chemotherapy regimen, randomisation before or within the first 28 days of chemotherapy, and institution. Chemotherapy consisted of mFOLFIRINOX (day 1 oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 50 mg, and fluorouracil 2400 mg/m2 over 46 h every 14 days for six cycles; all intravenous) or gemcitabine plus nab-paclitaxel (gemcitabine 1000 mg/m2 and nab-paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days for three cycles; both intravenous). SBRT was delivered as 40 Gy in five fractions, with two to four fractions delivered per week, with real-time radiotherapy quality assurance. Surgical resection was considered following induction therapy, followed by a planned further 12 weeks of adjuvant chemotherapy with either mFOLFIRINOX or gemcitabine plus capecitabine (28-day cycles of 1000 mg/m2 intravenous gemcitabine administered on days 1, 8, and 15 with 830 mg/m2 oral capecitabine twice daily administered on days 1-21). Participants deemed not suitable for surgery continued the same chemotherapy for an additional 12 weeks with reassessment for surgical suitability permitted, for a total planned duration of chemotherapy of 24 weeks. The primary endpoint was 12-month locoregional recurrence in the intention-to-treat population, with safety endpoints analysed by treatment received. The trial planned to recruit 120 patients but due to slow accrual closed to recruitment early on Jan 6, 2025. Trial closure and database lock occurred on July 21, 2026. This trial was registered with the Australian New Zealand Clinical Trial Registry (ACTRN12619000409178) and ClinicalTrials.gov (NCT04089150), and is complete. FINDINGS: Between Feb 26, 2020, and Jan 6, 2025, 74 participants (43 [58%] male, 31 [42%] female) were randomly assigned to chemotherapy and SBRT (n=49) or chemotherapy alone (n=25). After a median follow-up of 3·2 years (IQR 1·9-4·3), 12-month locoregional recurrence was 20·2% (95% CI 9·9-33·1) in the SBRT group and 52·0% (30·3-69·9) in the chemotherapy alone group (subdistribution hazard ratio 0·44 [95% CI 0·22-0·88]; p=0·022). Grade 3 or higher adverse events occurred in 33 (70%) of 47 participants in the SBRT group and 16 (64%) of 25 participants in the chemotherapy alone group (p=0·27), with one (4%) treatment-related death secondary to biliary tract infection in the chemotherapy alone group. The most common grade 3-4 adverse events were diarrhoea (seven [15%] in the SBRT group vs five [20%] in the chemotherapy alone group), and thromboembolic events (three [6%]) vs one [4%]). Overall grade 3 or higher serious adverse events occurred in 30 (64%) of 47 participants in the SBRT group, and 14 (56%) of 25 participants in the chemotherapy alone group (p=0·24). There were two serious adverse events attributable to SBRT; grade 2 small bowel obstruction and grade 3 pancreatitis. INTERPRETATION: In patients with high-risk, localised PDAC, the addition of SBRT to chemotherapy was associated with significantly reduced locoregional recurrence without a significant increase in toxicity and warrants further investigation in larger studies. FUNDING: Medical Research Future Fund, Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre (University of Sydney), and Gut Cancer Foundation, New Zealand.
引用
- Oar A, Kneebone A, Sjoquist KM, et al. Perioperative chemotherapy and stereotactic body radiotherapy versus perioperative chemotherapy alone in patients with high-risk, localised pancreatic cancer (MASTERPLAN): an open-label, phase 2, multicentre, randomised trial of the Australasian Gastro-Intestinal Trials Group. Lancet Oncol. 2026. PMID: 42914998. doi:10.1016/S1470-2045(26)00532-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。